Pomalidomide. TNF-α production inhibitor, treatment of multiple myeloma, treatment of myelofibrosis

Drugs of the Future

Volumn 36, Issue 10, 2011, Pages 741-750

  Galustian, C ^a,b   Dalgleish, A G ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 8; CASPASE 9; CYCLOOXYGENASE 2; DEXAMETHASONE; FAS ANTIGEN; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BONE MARROW; CANCER CELL; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; EFFECTOR CELL; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOCYTE; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOMA CELL; NEUTROPENIA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PLASMA CELL; REVIEW; SPLENOMEGALY; STROMA CELL; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84952983734     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.10.1641628     Document Type: Review

References (54)

1. Muller, G.W., Chen, R., Huang, S.-Y. et al. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999, 9(11): 1625-30. (Pubitemid 29274209)
2. Stirling, D.I., Chen, R.S.-C., Muller, G.W. (Celgene Corp.). Substituted 2- (2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels. EP 0925294, EP 1285916, EP 2070920, EP 2177517, EP 2305663, JP 2008050368, US 5635517, WO 1998003502.
3. Muller, G.W., Saindane, M.T., Ge, C., Chen, R. (Celgene Corp.). Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3- dione compounds. EP 1907373, JP 2008544993, US 2007004920, US 7994327, WO 2007005972.
4. Shah, J.H., Hunsucker, K.A., Conner, B.P. et al. (Children's Medical Center Corp.). Synthesis of 3-amino-thalidomide and its enantiomers. CA 2430669, EP 1353672, JP 2004536784, JP 2009108077, US 2004147558, US 7812169, WO 2002064083.
5. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173(3): 699-703.
6. Galustian, C., Labarthe, M.C., Bartlett, J.B., Dalgleish, A.G. Thalidomidederived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther 2004, 4(12): 1963-70. (Pubitemid 39627147)
7. Marriott, J.B., Clarke, I.A., Dredge, K., Muller, G., Stirling, D., Dalgleish, A.G. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002, 130(1): 75-84.
8. Dredge, K., Marriott, J.B., Todryk, S.M., Muller, G.W., Chen, R., Stirling, D.I., Dalgleish, A.G. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002, 168(10): 4914-9. (Pubitemid 34495953)
9. Schafer, P.H., Gandhi, A.K., Loveland, M.A. et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003, 305(3): 1222-32. (Pubitemid 36618002)
10. Payvandi, F., Wu, L., Naziruddin, S.D. et al. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKCtheta activation and enhancing the DNA-binding activity of AP-1 but not NFkappaB, OCT-1, or NF-AT. J Interferon Cytokine Res 2005, 25(10): 604-16. (Pubitemid 41507816)
11. Xu, W., Celeridad, M., Sankar, S., Webb, D.R., Bennett, B.L. CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet. Clin Immunol 2008, 128(3): 392-9.
12. Sharma, A., Khan, R., Joshi, S., Kumar, L., Sharma, M. Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk Lymphoma 2010, 51(5): 920-7.
13. Gorgun, G., Calabrese, E., Soydan, E. et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010, 116(17): 3227-37.
14. Galustian, C., Meyer, B., Labarthe, M.C. et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009, 58(7): 1033-45.
15. Zhu, D., Corral, L.G., Fleming, Y.W., Stein, B. Immunomodulatory drugs Revlimid((R)) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008, 57(12): 1849-59.
16. Reddy, N., Hernandez-Ilizaliturri, F.J., Deeb, G. et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008, 140(1): 36-45. (Pubitemid 350233246)
17. Feng, X., Yan, J., Wang, Y. et al. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol Immunol, 47(14): 2388-96.
18. Schutt, P., Brandhorst, D., Stellberg, W. et al. Immune parameters in multiple myeloma patients: Influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006, 47(8): 1570-82. (Pubitemid 44364023)
19. Blanco, B., Perez-Simon, J.A., Sanchez-Abarca, L.I. et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107(9): 3575-83.
20. Blanco, B., Perez-Simon, J.A., Sanchez-Abarca, L.I. et al. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica 2009, 94(7): 975-83.
21. Hideshima, T., Chauhan, D., Shima, Y. et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96(9): 2943-50.
22. Shalapour, S., Zelmer, A., Pfau, M. et al. The thalidomide analogue, CC- 4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 2006, 12(18): 5526-32. (Pubitemid 44497270)
23. st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 4926.
24. Escoubet-Lozach, L., Lin, I.L., Jensen-Pergakes, K. et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69(18): 7347-56.
25. Schafer, P.H., Zhang, L.H., Muller, G., Stirling, D., Bartlett, B. Pomalidomide inhibits MM proliferation in vitro via enhanced expression of tumor suppressor genes. Clin Lymphoma Myeloma & Leukemia 2009, 9(Suppl. 1): B447.
26. Li, S., Pal, R., Monaghan, S.A. et al. IMiD(R) immunomodulatory compounds block C/EBP{beta} translation through eIF4E downregulation resulting in inhibition of MM. Blood 2011, 117(19): 5157-65.
27. Verhelle, D., Corral, L.G., Wong, K. et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67(2): 746-55. (Pubitemid 46192215)
28. Anderson, G., Gries, M., Kurihara, N. et al. Thalidomide derivative CC- 4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006, 107(8): 3098-105.
29. Mitsiades, N., Mitsiades, C.S., Poulaki, V. et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002, 99(12): 4525-30. (Pubitemid 34627223)
30. Liu, W.M., Henry, J.Y., Meyer, B., Bartlett, J.B., Dalgleish, A.G., Galustian, C. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 2009, 101(5): 803-12.
31. Dredge, K., Horsfall, R., Robinson, S.P. et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005, 69(1-2): 56-63. (Pubitemid 40410468)
32. Lu, L., Payvandi, F., Wu, L. et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009, 77(2): 78-86.
33. Gupta, D., Treon, S.P., Shima, Y. et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001, 15(12): 1950-61. (Pubitemid 33115003)
34. Xu, Y., Li, J., Ferguson, G.D. et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 2009, 114(2): 338-45.
35. Ferguson, L.R., Philpott, M. Cancer prevention by dietary bioactive components that target the immune response. Curr Cancer Drug Targets 2007, 7(5): 459-64. (Pubitemid 47196205)
36. Tsenova, L., Mangaliso, B., Muller, G., Chen, Y., Freedman, V.H., Stirling, D., Kaplan, G. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob Agents Chemother 2002, 46(6): 1887-95. (Pubitemid 34535212)
37. Raghupathy, R., Billett, H.H. Promising therapies in sickle cell disease. Cardiovasc Hematol Disord Drug Targets 2009, 9(1): 1-8.
38. Teo, S.K., Chen, Y., Muller, G.W., Chen, R.S., Thomas, S.D., Stirling, D.I., Chandula, R.S. Chiral inversion of the second generation IMiD CC-4047 (ACTIMID) in human plasma and phosphate-buffered saline. Chirality 2003, 15(4): 348-51. (Pubitemid 36459442)
39. Hayashi, T., Hideshima, T., Akiyama, M. et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. Br J Haematol 2005, 128(2): 192-203.
40. Streetly, M.J., Gyertson, K., Daniel, Y., Zeldis, J.B., Kazmi, M., Schey, S.A. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008, 141(1): 41-51. (Pubitemid 351350609)
41. nd Am Soc Hematol Annu Meet (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 864.
42. Infante, J.R., Jones, S.F., Bendell, J. et al. Phase I dose escalation study of pomalidomide in combination with gemcitabine in patients (pts) with untreated metastatic carcinoma of the pancreas. Gastrointest Cancers Symp (Jan 15-17, San Francisco) 2009, Abst 206.
43. Breitkreutz, I., Anderson, K.C. Thalidomide in multiple myeloma - Clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 2008, 4(7): 973-85.
44. Schey, S.A., Fields, P., Bartlett, J.B. et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004, 22(16): 3269-76. (Pubitemid 41103682)
45. st Annu Soc Hematol Annu Meet (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 301.
46. Lacy, M.Q., Hayman, S.R., Gertz, M.A. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009, 27(30): 5008-14.
47. Lacy, M.Q., Hayman, S.R., Gertz, M.A. et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010, 24(11): 1934-9.
48. Schey, S., Ramasamy, K. Pomalidomide therapy for myeloma. Expert Opin Investig Drugs 2011, 20(5): 691-700.
49. nd Am Soc Hematol Annu Meet (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 859.
50. nd Am Soc Hematol Annu Meet (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 863.
51. Tefferi, A., Verstovsek, S., Barosi, G. et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009, 27(27): 4563-9.
52. Mesa, R.A., Pardanani, A.D., Hussein, K. et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010, 85(2): 129-30.
53. nd Am Soc Hematol Annu Meet (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 4109.
54. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28 (18, Suppl.): Abst e13077.